NEW YORK (Reuters Health) – A new biomarker – tumor-associated CD68+ macrophages — predicts poor outcomes in patients with classic Hodgkin’s lymphoma, new research indicates. About 20% of…
NEW YORK (Reuters Health) – A normal coronary artery calcium (CAC) scan in middle-age appears to have a “warranty period” of about four years, during which the patient…
NEW YORK (Reuters Health) – With small breast cancers, doing complete axillary dissections only for positive sentinel lymph node biopsies (SNLB) yields the same 10-year survival – roughly…
NEW YORK (Reuters Health) – Use of insulin glargine or detemir rather than NPH insulin does not reduce the risk of ketoacidosis in children and adolescents with type…
NEW YORK (Reuters Health) – Injection of Macroplastique (Uroplasty), a urethral bulking agent, can improve female stress urinary incontinence for at least two years, new research shows. Exactly…
NEW YORK (Reuters Health) – There’s no good evidence that maintenance therapy improves the outcome of small-cell lung cancer (SCLC), according to a meta-analysis published February 25th in…
NEW YORK (Reuters Health) – Some patients with ocular hypertension are at low risk of progressing to open-angle glaucoma and don’t need treatment, research shows. But for patients…
NEW YORK (Reuters Health) – When statins alone can’t reverse dyslipidemia, the thyroid hormone analogue eprotirome may be helpful, new research suggests. In a 12-week study of 189…
NEW YORK (Reuters Health) – Four out of five children with juvenile idiopathic arthritis had a good clinical response to abatacept during a long-term open-label extension trial. The…
NEW YORK (Reuters Health) – A treatment called DRIFT (Drainage, Irrigation, and Fibrinolytic Therapy) may improve developmental outcomes and survival in preterm infants with posthemorrhagic cerebral ventricular dilatation,…